New hope for hard-to-treat breast cancer: drug combo targets triple positive tumors
NCT ID NCT07612215
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called elacestrant, combined with two standard biologic therapies, in people with advanced triple positive breast cancer (ER+, PR+, HER2+). The goal is to see if the combination can slow or stop cancer growth. About 50 women aged 18 and older will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ER POSITIVE, HER2 POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.